Why the study?
Percutaneous techniques have been developed for symptomatic HFrEF patients with specific phenotypes requiring non-pharmacological treatment, necessitating an overview of transcatheter devices and selection criteria.
Transcatheter interventions offer a growing armamentarium for treating specific phenotypes of HFrEF, such as valvular heart disease, when added to optimal medical therapy.
May guide device selection in select HFrEF phenotypes with valvular disease; leaves open definitive outcome data from ongoing trials.
Pharmacological treatment is the cornerstone therapy of heart failure with reduced ejection fraction (HFrEF). In addition, several percutaneous techniques have been developed to treat symptomatic patients, with specific heart failure (HF) phenotypes (e.g., valvular heart disease) that require non-pharmacological treatment. Given their prognostic relevance, it is imperative to deliver high-level patient care. This review provides a clinical overview on the available data regarding transcatheter devices in the armamentarium of contemporary interventional cardiologists, focusing on the clinical and anatomical selection criteria.
No takes yet. Share an insight, caveat, or question.
Sisinni et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: